Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Dupilumab safe, effective for atopic dermatitis

06 May 2018
Childhood atopic dermatitis or eczema takes a heavy toll not just physically and emotionally, but financially as well

Dupilumab, at dose regimens of 300 mg once weekly (qw) or once every 2 weeks (q2w), is effective and safe for atopic dermatitis, a recent meta-analysis has shown.

Pooled analysis of six trials (n=2,447) revealed that there was a significant decrease in the Eczema Area and Severity Index (EASI) scores following dupilumab treatment (standardized mean difference [SMD], –0.89; 94 percent CI, –1.00 to –0.78; p<0.00001).

The effect remained significant in both the 300 mg qw (SMD, –0.93; –1.10 to –0.76; p<0.00001) and q2w (SMD, –0.86; –1.02 to –0.71; p<0.00001) dosing regimens.

Dupilumab was better than placebo even when using other efficacy measures: percentage of body surface area (SMD, –0.83; –0.90 to –0.75; p<0.00001), Investigators Global Assessment response (risk ratio [RR], 3.82; 3.23–4.51; p<0.00001), pruritus numeric rating scale score (SMD, –0.81; –0.96 to –0.66; p<0.00001) and Dermatology Life Quality Index (SMD, –0.78; –0.89 to –0.66; p<0.00001).

In all cases above, both dosing regimens were significantly effective.

While all trials reported adverse events, the overall rates were statistically similar between dupilumab and placebo (42 percent vs 43 percent; RR, 1.0; 0.96–1.04; p=0.83). The rates of patients with ≥1 adverse event for the 300-mg qw and q2w dosing regimens were 32.8 percent (RR, 0.99; 0.94–1.05; p=0.81) and 41.9 percent (RR, 1.0; 0.94–1.06; p=0.97), respectively.

Accessing the databases of CBM, the Cochrane Library, Embase and PubMed, researchers identified randomized controlled trials of dupilumab treatment on adult atopic dermatitis patients. Observational, case-control and nonblinded studies were excluded from the meta-analysis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.